logo
No need for ‘ventriloquists' to give NHS patients a voice

No need for ‘ventriloquists' to give NHS patients a voice

Independent7 hours ago
Patients do not need 'ventriloquists' from arm's length bodies to speak for them, and more weight should be given to the likes of MPs and councillors, according to the Health Secretary.
Wes Streeting suggested the patient safety landscape is 'cluttered', with NHS leaders receiving 'competing and contradictory instructions' from different organisations.
He also said the creation of 'totally undemocratic' organisations is 'self infantilising' on politicians.
It comes as reports from over the weekend suggested hundreds of bodies that oversee and run parts of the health service will be axed under the upcoming 10-year health plan.
This could include Healthwatch England, the National Guardian's Office and the Health Services Safety Investigations Body.
In March, Prime Minister Sir Keir Starmer also unveiled plans to scrap NHS England in a bid to slash bureaucracy and duplication.
When asked about the reports on Healthwatch England and other organisations at the Local Government Association's annual conference in Liverpool on Tuesday, Mr Streeting said: 'There are way too many checkers and not enough doers in the system.
'And I think there are lots of ways in which we have tried to create new bodies to fulfil the failure of other parts of the state to do their job effectively.
'I mean, the revolution we're leading in patient voice will mean we can get rid of some of the intermediaries, and we don't need ventriloquists to speak for patients, patients can speak for ourselves if we're given the opportunity to do it.'
He also called for 'more weight' to be given to democratically elected representatives, adding that some organisations were created to 'do the jobs politicians should be doing'.
'We're councillors, leaders, cabinet members, mayors and Members of Parliament, and at the moment, I think lots of us would feel that as elected representatives, that we don't have enough sense of agency and partnership and democratic accountability that I think we are owed,' Mr Streeting said.
'I think this actually speaks to the corrosion of of our democracy and politics more generally; we keep on inventing a whole load of organisations to do the jobs that politicians should be doing, and thereby sending a message to the public, that voting doesn't change anything, that we don't trust politicians and government to lead things locally or nationally, so we create a totally undemocratic set of organisations to do things for us, because we almost don't trust ourselves.
'And not only, I think, is that self infantilising on the politicians, it's also wasting public money that is in scarce supply. So we're taking the axe to lots of those organisations.'
Mr Streeting also vowed to 'take a much more data and evidence based approach to quality and safety and try and declutter the patient safety landscape'.
He said: 'I understand how we got here. Many of my predecessors, with good intentions, encountered challenges around patient safety and quality.
'They could see the bodies that already existed weren't doing an effective enough job.
'Rather than grasp to nettle and sort those organisations out, they created new organisations.
'If they felt that regulations weren't working effectively, they introduced more regulations, and in doing so, gave false comforts themselves and false comfort to the country that by adding more organisations and more regulations, we will necessarily be safer.
'We have cluttered the patient safety landscape to such an extent that the poor people on the front line and NHS leaders are on the receiving end of a whole number of sometimes competing and contradictory instructions from a wide range of organisations all trying to do the same job.'
Mr Streeting also vowed to start working with local government on NHS winter planning 'much earlier' this year.
He said: 'I am under no illusion about how serious the pressures are, and you'll be pleased to know that we are going much faster this year on winter planning, and we'll be engaging with you much earlier in the year on preparations for winter.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BREAKING NEWS Urgent recall for life-saving device over dangerous defect
BREAKING NEWS Urgent recall for life-saving device over dangerous defect

Daily Mail​

time42 minutes ago

  • Daily Mail​

BREAKING NEWS Urgent recall for life-saving device over dangerous defect

An entire line of defibrillators has been urgently recalled after issues with the devices' circuits caused some of them to fail. The federal government issued a notice for medical technology firm Stryker's HeartSine samaritan Public Access Defibrillator (PAD) on June 24. 'A manufacturing problem related to a circuit board component may impair the device's ability to function or cause failure,' it said. 'This failure could occur at any point when the device is holding a charge. This may be in preparation to deliver therapy, while delivering a shock, or after shock delivery. 'The device becomes inoperable after the failure occurs.' The notice said the defect was spotted during quality testing, not patient use. The source of the issue was the Pad-Pak, a single-use battery and electrode cartridge containing the battery to power the defibrillator and two electrode pads. Users should check their AED serial number to see if it is affected, noting the devices are part of a subset of HeartSine samaritan PAD Models 350P, 360P, 450P and 500P. The affected devices are part of a subset of serial numbers beginning with 21, 22, 23 or 24, and are then followed by the letter B, D, E, G or H. Stryker said users should continue monitoring their PAD device to ensure the status indicator is flashing green every five to 10 seconds. They should contact Stryker immediately if the status indicator is flashing red, or they can hear continuous beeping or the voice prompt 'Warning, Low Battery'. Alternatively, they should contact the company if no status indicator is displayed. For further information, Stryker can be reached on 02 9170 9131 or through email at

Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast cancer patients ‘denied life-extending drugs because of unfair system'

Rhyl Journal

timean hour ago

  • Rhyl Journal

Breast cancer patients ‘denied life-extending drugs because of unfair system'

Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'

Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast cancer patients ‘denied life-extending drugs because of unfair system'

North Wales Chronicle

timean hour ago

  • North Wales Chronicle

Breast cancer patients ‘denied life-extending drugs because of unfair system'

Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store